![]() |
市場調查報告書
商品編碼
2088763
乾血斑採集卡市場:2026-2032年全球市場預測(依產品類型、技術、檢體類型、應用、最終用戶及通路分類)Dried Blood Spot Collection Cards Market by Product Type, Technology, Sample Type, Application, End User, Distribution Channel - Global Forecast 2026-2032 |
||||||
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計到 2032 年,乾血斑採集卡市場將成長至 5.9564 億美元,複合年成長率為 5.64%。
| 主要市場統計數據 | |
|---|---|
| 基準年 2025 | 4.0541億美元 |
| 預計年份:2026年 | 4.2783億美元 |
| 預測年份 2032 | 5.9564億美元 |
| 複合年成長率 (%) | 5.64% |
乾血斑 (DBS) 採集卡正從專門用於新生兒篩檢的工具,發展成為更廣泛、更分散的採樣平台,可用於新生兒篩檢、感染疾病監測、治療藥物監測、毒理學、基因組學和人群健康調查。其核心提案已得到充分證實:毛細血管血可採集在檢驗的濾紙上,乾燥後,無需依賴低溫運輸即可運輸,並可使用免疫檢測、PCR 和質譜分析等工作流程進行分析。
隨著醫療系統擴展遠端醫療、流行病學監測和以患者為中心的臨床試驗設計,幹血斑 (DBS) 採集卡的格局正在重塑,檢測模式正從依賴血液採集的集中式檢測轉向居家、社區和小規模檢體採集模式。這種轉變的勢頭日益強勁。
人工智慧為整個乾血斑(DBS)工作流程增添了價值,但當與檢驗的檢查室方法相結合時,其影響最為顯著。人工智慧驅動的影像分析有助於進行樣本品質評估,在檢測前識別出填充不足、過飽和、分層或受污染的檢體,從而幫助檢查室減少不合格品和重新取樣的負擔。
在亞太地區,由於新生兒篩檢的現代化、大規模公共衛生舉措以及中國、印度、日本、韓國和澳洲等國本土診斷設備製造業的成長,市場正在不斷擴張。該地區市場應用的主要驅動力是全國範圍內篩檢的擴展、感染疾病監測的加強,以及對能夠在人口稠密的都市區地區和偏遠社區之間高效運輸的檢體格式的需求。北美仍然是一個高價值地區,美國和加拿大擁有成熟的新生兒篩檢系統、強大的臨床實驗室基礎設施、完善的生物銀行庫以及廣泛採用的分散式臨床研究模式。
東協的需求主要受以下因素驅動:全民健康覆蓋範圍的擴大、新生兒篩檢的進步、感染疾病監測的加強,以及對適用於島嶼、邊境和農村地區的檢體採集方式的需求。海灣合作理事會(GCC)國家正在投資預防醫學、基因組學、罕見病篩檢和高規格檢查室基礎設施,從而催生了對具有可追溯性、檢驗驗證和合規性等特點的高品質乾血斑(DBS)採集卡的需求。
美國透過州級新生兒篩檢計畫、CLIA認證檢查室、分散式臨床試驗和完善的公共衛生監測系統發揮主導作用。加拿大則強調與公共衛生體系的整合、州級篩檢計畫以及在偏遠和北部地區實現公平的醫療服務取得。墨西哥和巴西在新生兒篩檢、感染疾病監測和分散式檢體採集方面看到了以可近性為核心的商業機會。英國、德國、法國、義大利和西班牙依賴成熟的臨床實驗室網路、嚴格的品質要求和規範的診斷流程,而俄羅斯的大片地區則對更持久的檢體採集方式產生了濃厚的興趣,以減少對複雜運輸條件的依賴。
行業領導者應優先考慮檢驗的卡片性能、堅固的包裝以及與自動化打孔、提取和數位追蹤系統的兼容性。在採購決策中,能夠證明批次間一致性、分析物穩定性、污染控制、防潮性能和法規文件的供應商變得越來越重要。
本執行摘要基於公共衛生機構、監管指南、標準化機構、同行評審文獻、臨床實驗室實踐參考資料以及公開產品文件的二手研究。主要資訊來源包括新生兒篩檢框架、美國疾病管制與預防中心 (CDC) 的乾血斑 (DBS) 應用案例、臨床實驗室標準協會 (CLSI) 關於血液採集品質的指南、美國食品藥物管理局(FDA) 對受目標產品的要求、符合國際標準化組織 (ISO) 標準的品質原則,以及已發表的 DBS 在診斷、監測和生物監測中應用的證據。
乾血斑 (DBS) 採集卡正逐漸成為分散式診斷、新生兒篩檢和公共衛生基礎設施的重要組成部分。其價值在於能夠實現小檢體採集、簡化運輸和可擴展的檢測,同時又不影響嚴格的檢驗、標準化的操作和檢查室品管。
The Dried Blood Spot Collection Cards Market is projected to grow by USD 595.64 million at a CAGR of 5.64% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 405.41 million |
| Estimated Year [2026] | USD 427.83 million |
| Forecast Year [2032] | USD 595.64 million |
| CAGR (%) | 5.64% |
Dried blood spot collection cards are moving from a specialized neonatal screening tool to a broader decentralized sampling platform for newborn screening, infectious disease surveillance, therapeutic drug monitoring, toxicology, genomics, and population health research. The core value proposition is well established: capillary blood can be collected on validated filter paper, dried, transported with reduced cold-chain dependence, and analyzed using immunoassay, PCR, and mass spectrometry workflows.
Demand is supported by verified public health use cases, including newborn screening programs coordinated through national and regional health systems and biomonitoring applications referenced by public health agencies such as the CDC. Industry participants are differentiating through card material consistency, sample traceability, automation compatibility, and compliance with ISO, CLSI, FDA, and laboratory quality requirements.
The dried blood spot collection cards landscape is being reshaped by the shift from centralized phlebotomy-dependent testing toward home, community, and low-volume sampling models. This transition gained momentum as healthcare systems expanded remote care, epidemiological surveillance, and patient-centric clinical trial designs.
A second structural shift is the convergence of DBS cards with high-sensitivity analytical platforms. Liquid chromatography-tandem mass spectrometry, molecular diagnostics, and multiplex assays have improved the utility of small-volume dried specimens. At the same time, manufacturers face higher expectations for lot-to-lot uniformity, contamination control, humidity protection, barcoding, and chain-of-custody documentation.
Artificial intelligence is adding value across the DBS workflow, but its impact is strongest when paired with validated laboratory methods. AI-enabled image analysis can support spot quality assessment by identifying underfilled, oversaturated, layered, or contaminated samples before testing, helping laboratories reduce rejection rates and recollection burden.
AI also supports demand planning, logistics optimization, and automated interpretation of high-throughput assay data. In regulated environments, however, AI must be governed by audit trails, bias controls, cybersecurity safeguards, and documented validation. The competitive advantage will come from combining DBS card reliability with transparent, compliant analytics rather than replacing laboratory expertise.
Asia-Pacific is expanding through newborn screening modernization, large population health initiatives, and growing domestic diagnostics manufacturing in China, India, Japan, South Korea, and Australia. The region's adoption is supported by national screening expansion, infectious disease monitoring, and the operational need for sample formats that can move efficiently across dense urban systems and hard-to-reach communities. North America remains a high-value region because the United States and Canada have mature newborn screening systems, strong clinical laboratory infrastructure, established biobanking capabilities, and broad adoption of decentralized clinical research models.
Latin America shows rising use in public health surveillance and access-focused diagnostics, with Brazil and Mexico acting as important adoption centers for neonatal screening, infectious disease monitoring, and community-based sample collection. Europe benefits from established screening programs, GDPR-driven data governance, accredited laboratory networks, and quality-oriented procurement that prioritizes validated substrates and documented traceability. The Middle East is building capacity through national genomics, preventive health programs, and laboratory modernization, while Africa demonstrates strong relevance for DBS cards in HIV, metabolic disease, maternal and child health, and remote population testing where transport simplicity and ambient stability are critical.
ASEAN demand is shaped by expanding universal health coverage, neonatal screening upgrades, infectious disease surveillance, and the need for sampling formats that work across island, border, and rural geographies. GCC countries are investing in preventive care, genomics, rare disease screening, and high-specification laboratory infrastructure, creating opportunities for premium dried blood spot collection cards with traceability, validated performance, and compliance features.
The European Union emphasizes harmonized quality systems, privacy-by-design data handling, CE-aligned diagnostic compliance, and validated clinical performance across laboratory networks. BRICS markets combine large patient populations with domestic manufacturing priorities and public health scale, making affordability, quality assurance, and scalable production essential. G7 countries lead in regulated clinical research, biomarker validation, newborn screening optimization, and automation adoption, while NATO-aligned procurement environments place additional emphasis on resilient medical supply chains, biosurveillance readiness, and secure sample traceability.
The United States leads through state newborn screening programs, CLIA-certified laboratories, clinical trial decentralization, and established public health surveillance capabilities, while Canada emphasizes public health integration, provincial screening programs, and equitable access across remote and northern communities. Mexico and Brazil present access-driven opportunities in neonatal screening, infectious disease monitoring, and decentralized sample collection. The United Kingdom, Germany, France, Italy, and Spain rely on mature clinical laboratory networks, strict quality requirements, and regulated diagnostic pathways, while Russia's large geography supports interest in durable sampling formats that reduce dependency on complex transport conditions.
China and India offer scale, local manufacturing momentum, expanding preventive care programs, and increasing use of molecular and mass spectrometry-based testing. Japan, South Korea, and Australia are advanced markets for precision diagnostics, quality-controlled sample handling, newborn screening refinement, and research applications. Across these countries, adoption is strongest where dried blood spot collection cards reduce collection burden, simplify logistics, support validated downstream analysis, and align with national laboratory quality standards.
Industry leaders should prioritize validated card performance, robust packaging, and compatibility with automated punching, extraction, and digital tracking systems. Procurement decisions increasingly favor suppliers that can prove lot consistency, analyte stability, contamination control, humidity protection, and regulatory documentation.
Organizations should build partnerships with clinical laboratories, public health agencies, and decentralized trial operators to align card design with real-world workflows. Investments in barcoding, sample-quality imaging, humidity indicators, tamper-evident packaging, and AI-supported logistics can improve operational reliability. Regional strategies should balance premium regulated markets with cost-efficient offerings for high-volume public health programs.
This executive summary is developed using secondary research from public health agencies, regulatory guidance, standards organizations, peer-reviewed literature, clinical laboratory practice references, and publicly available product documentation. Key sources considered include newborn screening frameworks, CDC dried blood spot applications, CLSI guidance on blood collection quality, FDA expectations for regulated products, ISO-aligned quality principles, and published evidence on DBS use in diagnostics, surveillance, and biomonitoring.
The methodology combines qualitative market assessment, regional policy review, technology trend mapping, and end-use evaluation across clinical diagnostics, research, public health, and pharmaceutical applications. Insights are validated by triangulating adoption drivers, regulatory constraints, laboratory workflow requirements, sample integrity considerations, and supply chain factors.
Dried blood spot collection cards are becoming a strategic component of decentralized diagnostics, newborn screening, and population health infrastructure. Their value lies in enabling small-volume sample collection, simplified transport, and scalable testing without eliminating the need for rigorous validation, standardized handling, and laboratory quality control.
Future adoption will depend on quality-controlled materials, regulatory readiness, automation compatibility, ambient sample stability, and digital sample traceability. Suppliers that combine proven card chemistry with workflow intelligence and regional market adaptation will be best positioned to address demand across clinical, research, and public health settings.